QNCX
Quince Therapeutics Inc

6,265
Mkt Cap
$192.1M
Volume
1.04M
52W High
$3.58
52W Low
$0.7203
PE Ratio
-2.83
QNCX Fundamentals
Price
$3.65
Prev Close
$3.45
Open
$3.46
50D MA
$1.82
Beta
0.16
Avg. Volume
392,297.09
EPS (Annual)
-$1.31
P/B
177.56
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Quince Therapeutics to Participate at Investor Events in December 2025
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that senior...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Brookline Capital Management Predicts QNCX FY2028 Earnings
Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Brookline Capital Management cut their FY2028 earnings estimates for shares of Quince Therapeutics in a report released on Thursday, November...
MarketBeat·11d ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX)
D. Boral Capital reissued a "buy" rating and issued a $4.00 price target on shares of Quince Therapeutics in a research note on Thursday...
MarketBeat·14d ago
News Placeholder
Quince Therapeutics (NASDAQ:QNCX) Announces Quarterly Earnings Results
Quince Therapeutics (NASDAQ:QNCX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus...
MarketBeat·15d ago
News Placeholder
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today provided an update on...
Business Wire·16d ago
News Placeholder
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the...
Business Wire·18d ago
News Placeholder
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the poster...
Business Wire·2mo ago
News Placeholder
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that the...
Business Wire·5mo ago
News Placeholder
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced that it will host...
Business Wire·10mo ago
News Placeholder
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that Dirk...
Business Wire·10mo ago

Latest QNCX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.